Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Cash: 2020-2024

Historic Change in Cash for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$47.7 million.

  • SAB Biotherapeutics' Change in Cash rose 418.82% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 200.24%. This contributed to the annual value of -$47.7 million for FY2024, which is 214.81% down from last year.
  • SAB Biotherapeutics' Change in Cash amounted to -$47.7 million in FY2024, which was down 214.81% from $41.5 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Change in Cash high stood at $41.5 million for FY2023, and its period low was -$47.7 million during FY2024.
  • Its 3-year average for Change in Cash is -$10.2 million, with a median of -$24.5 million in 2022.
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 329.96% in 2021, then slumped by 214.81% in 2024.
  • SAB Biotherapeutics' Change in Cash (Yearly) stood at $6.3 million in 2020, then soared by 329.96% to $26.9 million in 2021, then slumped by 190.95% to -$24.5 million in 2022, then surged by 269.48% to $41.5 million in 2023, then slumped by 214.81% to -$47.7 million in 2024.